Skip to content

Study · In vitro (cells) · mouse · 1994

6 results

Inhibitory effect of vasoactive intestinal peptide (VIP) on phagocytosis in mouse peritoneal macrophages.

Ichinose M, Sawada M, Maeno T

Regulatory peptides1 Dec 1994Cited by 13 (Europe PMC)

PMID7536335 (opens in a new tab)DOI10.1016/0167-0115(94)90543-6 (opens in a new tab)PepBankPUB-07536335
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In mouse peritoneal macrophages, VIP suppressed phagocytosis in a dose-dependent manner.

    In plain wordsIn mouse immune cells in a lab dish, VIP reduced their uptake of particles, more at higher doses.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreasePhagocytosis by peritoneal macrophages
    Study

    mousen: not reported in source

    Mouse peritoneal macrophages
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    This assay revealed that VIP suppressed phagocytosis in a dose-dependent manner.
  2. 02LabIn vitro (cells)Activity measurement

    In mouse peritoneal macrophages, a known VIP antagonist suppressed phagocytosis less than VIP did.

    In plain wordsIn mouse immune cells in a lab dish, VIP reduced particle uptake more than a known VIP-blocking compound did.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreasePhagocytosis suppression by VIP versus a VIP antagonist
    Study

    mousen: not reported in source

    Mouse peritoneal macrophages
    Comparator
    (N-Ac-Tyr1,D-Phe2)-GRF(1-29)-NH2 antagonist
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    A known VIP-antagonist (N-Ac-Tyr1,D-Phe2)-growth hormone-releasing factor (GRF) (1-29)-NH2 suppressed phagocytosis less than VIP.
  3. 03LabIn vitro (cells)Mechanism

    In mouse peritoneal macrophages, VIP suppressed phagocytosis more in Ca(2+)-free solution than in normal solution.

    In plain wordsIn mouse immune cells in a lab dish, VIP reduced particle uptake more without calcium than with normal calcium.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreaseVIP suppression of phagocytosis in Ca(2+)-free solution
    Study

    mousen: not reported in source

    Mouse peritoneal macrophages
    Comparator
    Normal solution
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Phagocytosis was suppressed by VIP further in Ca(2+)-free solution than in the normal solution.
  4. 04LabIn vitro (cells)Mechanism

    In mouse peritoneal macrophages, the degree of phagocytosis suppression by VIP was the same with or without the phosphodiesterase inhibitor IBMX.

    In plain wordsIn mouse immune cells in a lab dish, VIP reduced particle uptake equally with or without the enzyme blocker IBMX.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    No significant changeVIP suppression of phagocytosis with or without IBMX
    Study

    mousen: not reported in source

    Mouse peritoneal macrophages
    Comparator
    Without IBMX
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The degree of suppression by VIP was the same in the presence or the absence of IBMX.

Studies that did not test the peptide alone2

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  1. 05LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Activity measurement

    In mouse peritoneal macrophages, the VIP fragment VIP(1-12) did not suppress phagocytosis.

    In plain wordsIn mouse immune cells in a lab dish, the short VIP piece VIP(1-12) did not reduce particle uptake.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    No significant changePhagocytosis with the fragment VIP(1-12)
    Study

    mousen: not reported in source

    Mouse peritoneal macrophages
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    VIP(1-12) did not suppress phagocytosis.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  2. 06LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Activity measurement

    In mouse peritoneal macrophages, the VIP fragment VIP(10-28) suppressed phagocytosis more than VIP(1-28).

    In plain wordsIn mouse immune cells in a lab dish, the VIP piece VIP(10-28) reduced particle uptake more than VIP(1-28).

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreasePhagocytosis with the fragment VIP(10-28) versus VIP(1-28)
    Study

    mousen: not reported in source

    Mouse peritoneal macrophages
    Comparator
    VIP(1-28)
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    VIP(10-28) was more suppressive than VIP(1-28).

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 3 to 38Current

    28 Oct 2026, 02:04 UTC

    The same notice was added 36 times, first on 9 Oct 2026, 19:08 UTC. The status did not change between them.

    Study results updated

  2. Version 2

    9 Oct 2026, 12:41 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.